基于CD103+免疫细胞丰度对TROG 12.01和De-ESCALaTE随机试验中接受治疗的人乳头瘤病毒相关口咽癌进行预后分层
该研究汇总TROG 12.01和De-ESCALaTE两项随机试验数据,比较西妥昔单抗联合70Gy放疗与顺铂联合70Gy放疗在低危HPV相关口咽鳞癌中的疗效。主要终点为无失败生存期。结果显示,在西妥昔单抗联合放疗组中,CD103+肿瘤内免疫细胞高丰度(≥30%)患者3年无失败生存期为93%,低丰度(<30%)为74%, adjusted HR=0.22(95%CI 0.12-0.41),P<0.001;顺铂联合放疗组中无显著差异。
要点
- CD103+肿瘤内免疫细胞高丰度(≥30%)占27%。
- 西妥昔单抗联合放疗组中,高CD103组3年无失败生存期93%,低CD103组74%。
- 顺铂联合放疗组中,CD103高与低丰度间无失败生存期无显著差异。
核心结论
- CD103+肿瘤内免疫细胞表达可将西妥昔单抗联合放疗治疗的低危HPV相关口咽鳞癌分为预后极好和较差两个亚组。
- 高CD103群体是降强度试验的合理目标人群。
研究设计与样本
- 汇总TROG 12.01和De-ESCALaTE两项随机试验数据,比较西妥昔单抗联合70Gy放疗与顺铂联合70Gy放疗在低危HPV相关口咽鳞癌中的疗效。
- 低危定义为美国癌症联合委员会第7版III期(排除T1-2N1)或IV期(排除吸烟史>10包年者的N2b-c和/或远处转移)。
- 纳入所有有可用肿瘤样本的患者,TROG 12.01中159/182例,De-ESCALaTE中145/334例。
主要发现
- CD103+肿瘤内免疫细胞高丰度(≥30%)患者占27%。
- 中位随访3.2年。
- 西妥昔单抗联合放疗组中,高CD103组3年无失败生存期93%(95%CI 79%-98%),低CD103组74%(95%CI 63%-81%),调整后风险比=0.22(95%CI 0.12-0.41),P<0.001。
- 西妥昔单抗联合放疗组中,高CD103组3年总生存期100%,低CD103组86%(95%CI 76%-92%),P<0.001。
- 顺铂联合放疗组中,CD103高与低丰度间无失败生存期无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High CD103+ intratumoral immune cell (ITIC) abundance is associated with better prognosis in unselected patients with human papilloma virus-associated oropharyngeal squamous cell carcinoma (HPV-associated OPSCC) treated with cisplatin and radiotherapy (CIS/RT). Substituting cetuximab (CETUX) for CIS with RT in HPV-associated OPSCC resulted in inferior efficacy. Our aim was to determine whether quantification of CD103 ITIC could be used to identify a population of HPV-associated OPSCC with superior prognosis. PATIENTS AND METHODS: We pooled data from the TROG 12.01 and De-ESCALaTE randomized trials that compared CETUX/70GyRT with CIS/70GyRT in low-risk HPV-associated OPSCC: American Joint Committee on Cancer 7 stage III (excluding T1-2N1) or stage IV (excluding N2b-c if smoking history >10 pack-years and/or distant metastases), including all patients with available tumor samples. The primary endpoint was failure-free survival (FFS) in patients receiving CETUX/RT comparing CD103+ ITIC high (≥30%) versus low (<30%). High and low CD103 were compared using Cox regression adjusting for age, stage and trial. RESULTS: Tumor samples were available in 159/182 patients on TROG 12.01 and 145/334 on De-ESCALaTE. CD103+ ITIC abundance was high in 27% of patients. The median follow-up was 3.2 years. The 3-year FFS in patients treated with CETUX/RT was 93% [95% confidence interval (CI) 79% to 98%] in high CD103 and 74% (95% CI 63% to 81%) in low CD103 [adjusted hazard ratio = 0.22 (95% CI 0.12-0.41), P < 0.001]. The 3-year overall survival in patients treated with CETUX/RT was 100% in high CD103 and 86% (95% CI 76% to 92%) in low CD103, P < 0.001. In patients treated with CIS/RT, there was no significant difference in FFS. CONCLUSIONS: CD103+ ITIC expression separates CETUX/RT-treated low-risk HPV-associated OPSCC into excellent and poor prognosis subgroups. The high CD103 population is a rational target for de-intensification trials.
引用
- Rischin D, Mehanna H, Young RJ, et al. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. Ann Oncol. 2022. PMID: 35525376. doi:10.1016/j.annonc.2022.04.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。